Jpmorgan Chase & CO Context Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Context Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 173 shares of CNTX stock, worth $195. This represents 0.0% of its overall portfolio holdings.
Number of Shares
173Holding current value
$195% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding CNTX
# of Institutions
45Shares Held
56.9MCall Options Held
0Put Options Held
0-
Deep Track Capital, LP Greenwich, CT7.42MShares$8.38 Million0.54% of portfolio
-
Nextech Invest Ag7.42MShares$8.38 Million2.37% of portfolio
-
Avidity Partners Management LP Dallas, TX7.42MShares$8.38 Million0.89% of portfolio
-
Great Point Partners LLC Greenwich, CT6.93MShares$7.84 Million6.28% of portfolio
-
Blue Owl Capital Holdings LP New York, NY5.41MShares$6.11 Million3.5% of portfolio
About Context Therapeutics Inc.
- Ticker CNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,966,100
- Market Cap $18M
- Description
- Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...